Several reports have demonstrated that Nrf2 silencing in cancer cells could decrease cell proliferation and enhance sensitivity to chemotherapeutic agents in lung, gallbladder, and ovarian tumors (Meijerman et al., 2008; Singh et al., 2008). This evidence concerns the gene NFE2L2 and cancer.